Skip to main content
Erschienen in: Digestive Diseases and Sciences 2/2024

29.11.2023 | Original Article

Vaccine-Preventable Illness Leads to Adverse Outcomes in Liver Transplant Recipients

verfasst von: Aalam Sohal, Isha Kohli, Hunza Chaudhry, Ishandeep Singh, Kirti Arora, Shivam Kalra, Dino Dukovic, Marina Roytman

Erschienen in: Digestive Diseases and Sciences | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Liver transplant recipients (LTR) and patients with chronic liver disease (CLD) are at an increased risk of infections.

Aims

The objective of our study was to assess the incidence, and impact of vaccine preventable illness (VPI) on outcomes in LTR.

Methods

National Inpatient Sample (NIS) 2016–2020 was used to identify adults (age > 18) hospitalized LTR using ICD-10 codes. Data were collected on patient demographics, hospital characteristics, etiology of liver disease, hepatic decompensations and outcomes. Patients were stratified into two groups based on the presence or absence of VPI. Multivariate logistic regression analysis was performed to identify the association between VPI and outcomes.

Results

Out of 170,650 hospitalized LTR, 13.5% of the patients had VPI. The most common VPI was noted to be influenza (10.7%), followed by pneumococcal infection (2.7%). Incidence of mortality (6.9% vs. 1.6%, p < 0.001), ICU admissions (14.3% vs. 3.4%, p < 0.001), and acute kidney injury (AKI) (43.7% vs 37.35%, p < 0.001) was higher in the VPI group.

Conclusion

More than 13% of the LT hospitalizations had concomitant VPI. VPI in LTR was associated with worse outcomes. Our data suggests the need to identify factors associated with reduced vaccination rates and identify strategies to improve vaccination rates and responses in these patients.

Graphical Abstract

Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in cirrhosis. Hepatology (Baltimore, Md.) 2009;50:2022–2033.CrossRefPubMed Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in cirrhosis. Hepatology (Baltimore, Md.) 2009;50:2022–2033.CrossRefPubMed
4.
Zurück zum Zitat Jalan-Sakrikar N, Brevini T, Huebert RC, Sampaziotis F. Organoids and regenerative hepatology. Hepatology (Baltimore, Md) 2023;77:305.CrossRefPubMed Jalan-Sakrikar N, Brevini T, Huebert RC, Sampaziotis F. Organoids and regenerative hepatology. Hepatology (Baltimore, Md) 2023;77:305.CrossRefPubMed
6.
Zurück zum Zitat Pilar Hernandez MD, Martin P, Simkins J. Infectious complications after liver transplantation. Gastroenterol Hepatol 2015;11:741–753. Pilar Hernandez MD, Martin P, Simkins J. Infectious complications after liver transplantation. Gastroenterol Hepatol 2015;11:741–753.
8.
Zurück zum Zitat Rolak S, Said A, German R, Hayney MS, Caldera F. Optimizing immunization strategies in adult patients with chronic liver disease and liver transplant recipients. Gastroenterol Hepatol 2022;18:196–206. Rolak S, Said A, German R, Hayney MS, Caldera F. Optimizing immunization strategies in adult patients with chronic liver disease and liver transplant recipients. Gastroenterol Hepatol 2022;18:196–206.
9.
Zurück zum Zitat Caballero-Marcos A, Salcedo M, Alonso-Fernández R, Rodríguez-Perálvarez M, Spanish Society of Liver Transplantation (SETH) et al. Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients. Am J Transplant 2021;21:2876–2884. https://doi.org/10.1111/ajt.16599.CrossRefPubMed Caballero-Marcos A, Salcedo M, Alonso-Fernández R, Rodríguez-Perálvarez M, Spanish Society of Liver Transplantation (SETH) et al. Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients. Am J Transplant 2021;21:2876–2884. https://​doi.​org/​10.​1111/​ajt.​16599.CrossRefPubMed
10.
Zurück zum Zitat Rubin LG, Levin MJ, Ljungman P, Davies EG, Infectious Diseases Society of America, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014;58:44–100.CrossRef Rubin LG, Levin MJ, Ljungman P, Davies EG, Infectious Diseases Society of America, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014;58:44–100.CrossRef
11.
Zurück zum Zitat Danziger-Isakov L, Kumar D. Vaccination of solid organ transplant candidates and recipients: guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant. 2019;33:e13563.CrossRefPubMed Danziger-Isakov L, Kumar D. Vaccination of solid organ transplant candidates and recipients: guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant. 2019;33:e13563.CrossRefPubMed
12.
Zurück zum Zitat Feldman AG, Atkinson K, Wilson K, Kumar D. Under-immunization of the solid organ transplant population: an urgent problem with potential digital health solutions. Am J Transplant 2020;20:34–39.CrossRefPubMed Feldman AG, Atkinson K, Wilson K, Kumar D. Under-immunization of the solid organ transplant population: an urgent problem with potential digital health solutions. Am J Transplant 2020;20:34–39.CrossRefPubMed
13.
Zurück zum Zitat Kim YJ, Kim SI. Vaccination strategies in patients with solid organ transplant: Evidences and future perspectives. Clin Exp Vaccine Res 2016;5:125–131.CrossRefPubMedPubMedCentral Kim YJ, Kim SI. Vaccination strategies in patients with solid organ transplant: Evidences and future perspectives. Clin Exp Vaccine Res 2016;5:125–131.CrossRefPubMedPubMedCentral
14.
16.
Zurück zum Zitat Invasive Pneumococcal Disease in Solid Organ Transplant Recipients—10-Year Prospective Population SurveillanceKumar, D. et al.American Journal of Transplantation, Volume 7, Issue 5, 1209 - 1214 Invasive Pneumococcal Disease in Solid Organ Transplant Recipients—10-Year Prospective Population SurveillanceKumar, D. et al.American Journal of Transplantation, Volume 7, Issue 5, 1209 - 1214
17.
Zurück zum Zitat HCUP National Inpatient Sample (NIS). Healthcare cost and utilization project (HCUP). 2016–2019. Agency for healthcare research and quality. Rockville, MD. HCUP National Inpatient Sample (NIS). Healthcare cost and utilization project (HCUP). 2016–2019. Agency for healthcare research and quality. Rockville, MD.
18.
Zurück zum Zitat Elixhauser Comorbidity Software Refined for ICD-10-CM Healthcare Cost and Utilization Project (HCUP) . October 2021. Agency for healthcare research and quality. Rockville, MD. Elixhauser Comorbidity Software Refined for ICD-10-CM Healthcare Cost and Utilization Project (HCUP) . October 2021. Agency for healthcare research and quality. Rockville, MD.
25.
Zurück zum Zitat Kumar D, Humar A, Plevneshi A, Green K, Prasad GV, Siegal D, Toronto Invasive Bacterial Diseases Network, McGeer A. Invasive pneumococcal disease in solid organ transplant recipients–10-year prospective population surveillance. Am J Transplant 2007;7:1209–1214.CrossRefPubMed Kumar D, Humar A, Plevneshi A, Green K, Prasad GV, Siegal D, Toronto Invasive Bacterial Diseases Network, McGeer A. Invasive pneumococcal disease in solid organ transplant recipients–10-year prospective population surveillance. Am J Transplant 2007;7:1209–1214.CrossRefPubMed
27.
Zurück zum Zitat Levitsky J, Kalil A, Meza JL, Hurst GE, Freifeld A. Herpes zoster infection after liver transplantation: a case-control study. Liver Transpl 2005;11:320–325.CrossRefPubMed Levitsky J, Kalil A, Meza JL, Hurst GE, Freifeld A. Herpes zoster infection after liver transplantation: a case-control study. Liver Transpl 2005;11:320–325.CrossRefPubMed
29.
Zurück zum Zitat Pergam SA, Forsberg CW, Boeckh MJ et al. Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients. Transpl Infect Dis. 2011;13:15–23.CrossRefPubMedPubMedCentral Pergam SA, Forsberg CW, Boeckh MJ et al. Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients. Transpl Infect Dis. 2011;13:15–23.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Vink P, Ramon Torrell JM, Sanchez Fructuoso A, Kim SJ, Z-041 Study Group et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, Randomized Clinical Trial. Clin Infect Dis 2020;70:181–190. https://doi.org/10.1093/cid/ciz177.CrossRefPubMed Vink P, Ramon Torrell JM, Sanchez Fructuoso A, Kim SJ, Z-041 Study Group et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, Randomized Clinical Trial. Clin Infect Dis 2020;70:181–190. https://​doi.​org/​10.​1093/​cid/​ciz177.CrossRefPubMed
35.
Zurück zum Zitat Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices; CDC. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(No. RR-5):1–30. Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices; CDC. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(No. RR-5):1–30.
36.
Zurück zum Zitat Walti LN, Mugglin C, Mombelli M, Manuel O, Swiss Transplant Cohort Study et al. Vaccine-preventable infections among solid organ transplant recipients in Switzerland. JAMA Netw Open 2023;6:687.CrossRef Walti LN, Mugglin C, Mombelli M, Manuel O, Swiss Transplant Cohort Study et al. Vaccine-preventable infections among solid organ transplant recipients in Switzerland. JAMA Netw Open 2023;6:687.CrossRef
37.
Zurück zum Zitat Arentoft NS, Møller DL, Knudsen AD, Abdulovski R et al. Influenza in liver and kidney transplant recipients: incidence and outcomes. Microbiol Spectr 2023;11:e0322622.CrossRefPubMed Arentoft NS, Møller DL, Knudsen AD, Abdulovski R et al. Influenza in liver and kidney transplant recipients: incidence and outcomes. Microbiol Spectr 2023;11:e0322622.CrossRefPubMed
38.
Zurück zum Zitat Stockwell MS, Fiks AG. Utilizing health information technology to improve vaccine communication and coverage. Hum Vaccines Immunother 2013;9:1802–1811.CrossRef Stockwell MS, Fiks AG. Utilizing health information technology to improve vaccine communication and coverage. Hum Vaccines Immunother 2013;9:1802–1811.CrossRef
39.
Zurück zum Zitat Wilson K, Atkinson KM, Westeinde J. Apps for immunization: Leveraging mobile devices to place the individual at the center of care. Hum Vaccin Immunother 2015;11:2395–2399.CrossRefPubMedPubMedCentral Wilson K, Atkinson KM, Westeinde J. Apps for immunization: Leveraging mobile devices to place the individual at the center of care. Hum Vaccin Immunother 2015;11:2395–2399.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Szilagyi PG, Bordley C, Vann JC, Chelminski A, Kraus RM, Margolis PA et al. Effect of patient reminder/recall interventions on immunization rates: a review. Jama 2000;284:1820–1827.CrossRefPubMed Szilagyi PG, Bordley C, Vann JC, Chelminski A, Kraus RM, Margolis PA et al. Effect of patient reminder/recall interventions on immunization rates: a review. Jama 2000;284:1820–1827.CrossRefPubMed
Metadaten
Titel
Vaccine-Preventable Illness Leads to Adverse Outcomes in Liver Transplant Recipients
verfasst von
Aalam Sohal
Isha Kohli
Hunza Chaudhry
Ishandeep Singh
Kirti Arora
Shivam Kalra
Dino Dukovic
Marina Roytman
Publikationsdatum
29.11.2023
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 2/2024
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-023-08202-x

Weitere Artikel der Ausgabe 2/2024

Digestive Diseases and Sciences 2/2024 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.